Table 3.
Observed median survival, by indication, sex, type of diagnosis, age at diagnosis, and year of diagnosis
| Patient characteristics | Median survival (months, 95% CI) | |||||
|---|---|---|---|---|---|---|
| Metastatic breast cancer | Metastatic non-small cell lung cancer | Metastatic colorectal cancer | Metastatic ovarian cancer | Metastatic malignant melanoma | ||
| Type of diagnosis | De novo | 20.8 (19.6, 22.8) | 5.5 (5.3, 5.6) | 13.8 (13.3, 14.2) | NA | 12.7 (9.9, 15.3) |
| Recurrence | 19.8 (19.3, 20.5) | 4.16 (4, 4.4) | 11.7 (11.3, 12.2) | NA | 7 (6.5, 7.6) | |
| Age at diagnosis | < 50 y | 30.9 (29.1, 33.0) | 8.7 (7.8, 10.7) | 21.5 (19.9, 23.2) | 33.3 (26.2, 40.7) | 11.6 (10.2, 12.9) |
| 50 – 59 y | 27.6 (25.9, 29.5) | 6.43 (6.2, 6.9) | 22.5 (21.1, 24) | 29.2 (25.8, 35.1) | 11.2 (9.7, 13.1) | |
| 60 – 69 y | 23.9 (22.3, 25.3) | 5.8 (5.6, 6.0) | 18.4 (17.6, 19.1) | 24.1 (21.4, 27.1) | 9.1 (7.8, 10.4) | |
| 70 – 79 y | 18.8 (17.5, 19.9) | 4.59 (4.4, 4.8) | 11.7 (11.2, 12.2) | 21.2 (18.3, 24.1) | 6.2 (5.2, 7.3) | |
| 80 + y | 7.9 (7.3, 8.6) | 3.5 (3.3, 3.8) | 5 (4.7, 5.3) | 11.6 (7.8, 14.7) | 3.2 (2.9, 3.8) | |
| Year of diagnosis | 2005 – 2009 | 16.4 (15.4, 17.4) | 4.5 (4.3, 4.7) | 10.5 (10.2, 11.0) | 19.2 (17.1, 22.4) | 5.4 (4.8, 6.3) |
| 2010 – 2014 | 20.3 (19.4, 21.2) | 5.2 (4.9, 5.4) | 13.3 (12.8, 13.8) | 22.6 (20.1, 24.7) | 6.1 (5.6, 7.2) | |
| 2015 – 2018 | 26.2 (24.8, 28.2) | 6 (5.7, 6.3) | 15.7 (15.0, 16.5) | 31.5 (26.5, 35.4) | 11.5 (10.5, 13.5) | |
| Sex | Men | NA | 4.8 (4.6, 4.9) | 13.8 (13.3, 14.2) | NA | 6.8 (6.2, 7.6) |
| Women | NA | 5.7 (5.5, 5.9) | 11.7 (11.3, 12.2) | NA | 8.2 (7.3, 9.6) | |
CI Confidence interval, y year